Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Annexon, Inc. (ANNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 30,251 $ 29,106 $ 62,596 $ 56,104 General and administrative 7,440 8,303 16,337 16,731 Total operating expenses 37,691 37,409 78,933 72,835 Loss from operations Interest and other income, net 2,503 272 5,069 325 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share, basic and diluted 75,230,003 38,584,400 74,546,995 38,573,950 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,307 $ 2,117 $ 4,558 $ 4,076 General and administrative $ 2,353 $ 2,403 $ 4,709 $ 4,696 ANNEXON, INC. Cond..."
05/08/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 32,345 $ 26,998 General and administrative 8,897 8,428 Total operating expenses 41,242 35,426 Loss from operations Interest and other income, net 2,566 53 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 73,855,642 38,563,384 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,251 $ 1,959 General and administrative $ 2,356 $ 2,293 ANNEXON, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 144,120 $ 140,020 Short-term investme..."
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results $271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including Several Key Clinical Milestones across the Portfolio"
08/16/2021 8-K Quarterly results, Appointed a new director
Docs: "Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update – Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –"
05/17/2021 8-K Quarterly results
11/16/2020 8-K Quarterly results
Docs: "Initiated Phase 2 trial evaluating ANX005 in Huntington’s Disease . Initiated patient dosing in a Phase 2 trial designed to assess safety, tolerability, and biomarkers of target engagement and impact on neurodegeneration • Initiated Phase 1 first-in-human trial of ANX009. Initiated subcutaneous dosing of healthy volunteers with Annexon’s third clinical-stage drug candidate in a Phase 1 trial designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses • Completed enrollment of Guillain-Barré Syndrome Drug-Drug Interaction trial. Fully enrolled global Phase 1b DDI trial assessing safety and potential pharmacokinetic effect of ANX005 co-administered with IVIg in GBS patients. Data are anticipated in early 2021 Anticipated..."
09/08/2020 8-K Quarterly results
Docs: "Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy